Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.52 |
| ▸ | EIF5B | O60841 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 7/20 | 0.48 |
| ▸ | CCND1 | P24385 | 7/20 | 0.48 |
| ▸ | PLK4 | O00444 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | FLT4 | P35916 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875778 | 0.96 | OPA1 (0.52) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL224940 | 0.85 | CDK4 (0.61) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6329959 | 0.82 | CDK4 (0.60) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6325214 | 0.82 | SIRT2 (0.60) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL2881681 | 0.81 | CDK4 (0.54) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL1395793 | 0.80 | OPA1 (0.52) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL2343710 | 0.79 | CDK4 (0.63) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL15348911 | 0.79 | OPA1 (0.53) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL2018580 | 0.78 | OPA1 (0.53) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL8167094 | 0.78 | CDK4 (0.68) | CDK4CCND1PLK4AURKAFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2170870-B1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2170870-B1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| EP-2170870-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002806-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002806-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | PYCR1, DHPS, TYMP | OPA1 466/4885EIF5B 158/4885MET 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.